Kempen Herman J, Schranz Dorota B, Asztalos Bela F, Otvos James, Jeyarajah Elias, Drazul-Schrader Denise, Collins Heidi L, Adelman Steven J, Wijngaard Peter L J
The Medicines Company (Schweiz) GmbH, Talstrasse 59, 8002 Zürich, Switzerland.
Pacific Biomarkers LLC, 645 Elliott Avenue West, Suite 300, Seattle, WA 98119, USA.
J Lipids. 2014;2014:923903. doi: 10.1155/2014/923903. Epub 2014 Nov 12.
MDCO-216 is a complex of dimeric ApoA-IMilano and palmitoyl oleoyl phosphatidylcholine (POPC), previously shown to reduce atherosclerotic plaque burden. Here we studied the effect of incubation of human plasma or serum with MDCO-216 on cholesterol efflux capacity from J774 cells, on prebeta-1 high density lipoprotein (prebeta-1 HDL) and on HDL size assessed by proton nuclear magnetic resonance ((1)H-NMR). MDCO-216 incubated in buffer containing 4% human serum albumin stimulated both ABCA1-mediated efflux and ABCA1-independent cholesterol efflux from J774 macrophages. When incubated with human serum a dose- and time-dependent synergistic increase of the ABCA1-mediated efflux capacity were observed. Using a commercially available ELISA for prebeta-1 HDL, MDCO-216 as such was poorly detected (12-15% of nominal amount of protein). Prebeta-1 HDL was rapidly lost when human plasma alone is incubated at 37°C. In contrast, incubation of human plasma with MDCO-216 at 37°C produced a large amount of new prebeta-1 HDL. Native 2D electrophoresis followed by immunoblotting with an apoA-I antibody, which also detects ApoA-I Milano, confirmed the increase in prebeta-1 HDL upon incubation at 37°C. With the increase of prebeta-1 HDL, the concomitant disappearance of the small alpha-3 and alpha-4 HDL and MDCO-216 and an increase in the large alpha-1 and alpha-2 HDL were observed. Immunoblotting with Mab 17F3 specific for ApoA-I Milano showed the appearance of ApoA-I Milano in alpha-1 and alpha-2, but not in prebeta-1 HDL. (1)H-NMR analysis of plasma incubated with MDCO-216 confirmed rapid disappearance of small-sized HDL particles and increase of medium- and large-sized HDL particles accompanied with a decrease in total HDL particle number. In conclusion, incubation of human plasma or serum with MDCO-216 strongly enhanced ABCA1-mediated cholesterol efflux, caused a strong increase of prebeta-1 HDL, and drastically changed the distribution of HDL subpopulations. Overall, the results are in line with the hypothesis that MDCO-216 fuses with small alpha-migrating HDL particles forming larger particles containing both apoA-I WT and ApoA-I Milano, meanwhile liberating the endogenous wild-type apoA-I which enriches prebeta-1 HDL subpopulation.
MDCO - 216是二聚体载脂蛋白A - 米兰诺(ApoA - IMilano)与棕榈酰油酰磷脂酰胆碱(POPC)的复合物,此前已证明其可减轻动脉粥样硬化斑块负担。在此,我们研究了用MDCO - 216孵育人血浆或血清对J774细胞胆固醇流出能力、前β - 1高密度脂蛋白(prebeta - 1 HDL)以及通过质子核磁共振((1)H - NMR)评估的HDL大小的影响。在含有4%人血清白蛋白的缓冲液中孵育的MDCOMDCO - 216可刺激J774巨噬细胞的ABCA1介导的流出以及不依赖ABCA1的胆固醇流出。当与人类血清孵育时,观察到ABCA1介导的流出能力呈剂量和时间依赖性协同增加。使用市售的针对prebeta - 1 HDL的ELISA检测,MDCO - 216本身很难被检测到(为蛋白质标称含量的12 - 15%)。当单独将人血浆在37°C孵育时,prebeta - 1 HDL会迅速丢失。相反,在37°C下将人血浆与MDCO - 216孵育会产生大量新的prebeta - 1 HDL。天然二维电泳后用载脂蛋白A - I抗体进行免疫印迹(该抗体也可检测载脂蛋白A - 米兰诺),证实了在37°C孵育后prebeta - 1 HDL增加。随着prebeta - 1 HDL的增加,观察到小的α - 3和α - 4 HDL以及MDCO - 216同时消失,而大的α - 1和α - 2 HDL增加。用对载脂蛋白A - 米兰诺特异的单克隆抗体Mab 17F3进行免疫印迹显示,载脂蛋白A - 米兰诺出现在α - 1和α - 2 HDL中,而不在prebeta - 1 HDL中。对与MDCO - 216孵育的血浆进行(1)H - NMR分析证实,小尺寸HDL颗粒迅速消失,中尺寸和大尺寸HDL颗粒增加,同时HDL颗粒总数减少。总之,用人血浆或血清与MDCO - 216孵育可强烈增强ABCA1介导的胆固醇流出,导致prebeta - 1 HDL大幅增加,并显著改变HDL亚群的分布。总体而言,这些结果符合以下假设:MDCO - 216与小的α迁移HDL颗粒融合形成同时含有载脂蛋白A - I野生型(apoA - I WT)和载脂蛋白A - 米兰诺的更大颗粒,同时释放内源性野生型载脂蛋白A - I,从而使prebeta - 1 HDL亚群富集。